Obesity is having an excessive amount of body fat in relation to lean body mass that may impair health.
The primary cause is an energy imbalance between calories consumed and expended.
Treatment goals include to lose 5-10% of body weight or 0.5-1 kg (1-2 lb)/week for 6 months and regain of <3 kg in 2 years and sustained reduction of waist circumference of at least 4 cm.
Strategies are aiming for realistic goals and a multidisciplinary approach that is a combination of dietary change, physical activity and behavioral modification.
Mothers who adhere to a healthy lifestyle during their offspring’s childhood and adolescence appear to substantially lower the risk of obesity in their children, suggests a recent study. Of note, observing a healthy lifestyle in both mothers and their children leads to an even lower risk of offspring obesity.
A nasal device that reduces the ability to smell can lead to weight loss and changes in dietary preference for sweet stuff in adults younger than 50 years with obesity, suggesting a novel approach to managing obesity, according to a pilot study presented at the recent European Congress on Obesity (ECO) in Vienna, Austria.
A recent study shows that poor sleep quality may lead to junk food cravings, which when adjusted for covariates correlate with an elevated risk of obesity, diabetes and other health problems. In addition, night-time snacking is associated with increased risk of diabetes.
Individuals with obesity but without diabetes experienced significant weight reduction with daily doses of the glucagon-like peptide-1 receptor agonist semaglutide, according to a recent study presented at ENDO 2018.
Individuals with severe obesity who undergo Roux-en-Y gastric bypass (RYGB) may have a higher risk of nonvertebral fractures than those who undergo adjustable gastric banding (AGB), according to a study presented at the recent ENDO 2018 sessions.
Eating slower was associated with reduced body mass index (BMI) and waist circumference, as well as a lower risk of obesity than eating faster in people with type 2 diabetes, suggests a longitudinal observational study.
Patients who lose ≥8 percent of their excess weight via a 1-month-long surgeon-recommended low-calorie diet prior to undergoing primary vertical sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) have a greater rate of excess weight loss up to 1 year following the procedure, a recent study found.
Women who undergo a hysterectomy with bilateral ovarian conservation appear to have an elevated risk of cardiovascular (CV) and metabolic disease, particularly those who undergo the procedure at age 35 or younger, a recent study found.
Gastric bypass surgery in addition to intensive lifestyle and medical intervention led to reductions in HbA1c, blood pressure, and cholesterol levels up to 5 years post-surgery in patients with type 2 diabetes, though the effects of surgery appeared to decrease over time, according to results of the Diabetes Surgery Study.
Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.